1	1	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Introduction	_	_	NN	_	_	_	_	_


1	Triple-negative	_	_	JJ	_	_	_	_	_
2	breast	_	_	NN	_	_	_	_	_
3	cancer	_	_	NN	_	_	_	_	_
4	(	_	_	-LRB-	_	_	_	_	_
5	TNBC	_	_	NNP	_	_	_	_	_
6	)	_	_	-RRB-	_	_	_	_	_
7	is	_	_	VBZ	_	_	_	_	_
8	a	_	_	DT	_	_	_	_	_
9	heterogeneous	_	_	JJ	_	_	_	_	_
10	disease	_	_	NN	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	characterized	_	_	VBN	_	_	_	_	_
13	by	_	_	IN	_	_	_	_	_
14	aggressive	_	_	JJ	_	_	_	_	_
15	clinical	_	_	JJ	_	_	_	_	_
16	behavior	_	_	NN	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	poor	_	_	JJ	_	_	_	_	_
19	prognosis	_	_	NN	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	a	_	_	DT	_	_	_	_	_
22	significantly	_	_	RB	_	_	_	_	_
23	increased	_	_	VBN	_	_	_	_	_
24	risk	_	_	NN	_	_	_	_	_
25	of	_	_	IN	_	_	_	_	_
26	relapse	_	_	NN	_	_	_	_	_
27	,	_	_	,	_	_	_	_	_
28	and	_	_	CC	_	_	_	_	_
29	shorter	_	_	JJR	_	_	_	_	_
30	survival	_	_	NN	_	_	_	_	_
31	rates	_	_	NNS	_	_	_	_	_
32	than	_	_	IN	_	_	_	_	_
33	patients	_	_	NNS	_	_	_	_	_
34	affected	_	_	VBN	_	_	_	_	_
35	by	_	_	IN	_	_	_	_	_
36	other	_	_	JJ	_	_	_	_	_
37	molecular	_	_	JJ	_	_	_	_	_
38	subtypes	_	_	NNS	_	_	_	_	_
39	of	_	_	IN	_	_	_	_	_
40	breast	_	_	NN	_	_	_	_	_
41	cancer	_	_	NN	_	_	_	_	_
42	.	_	_	.	_	_	_	_	_


1	TNBC	_	_	NNP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	clinically	_	_	RB	_	_	_	_	_
4	defined	_	_	VBN	_	_	_	_	_
5	as	_	_	IN	_	_	_	_	_
6	tumors	_	_	NNS	_	_	_	_	_
7	that	_	_	WDT	_	_	_	_	_
8	lack	_	_	VBP	_	_	_	_	_
9	expression	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	estrogen	_	_	NN	_	_	_	_	_
13	receptor	_	_	NN	_	_	_	_	_
14	(	_	_	-LRB-	_	_	_	_	_
15	ER	_	_	NN	_	_	_	_	_
16	)	_	_	-RRB-	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	progesterone	_	_	NN	_	_	_	_	_
19	receptor	_	_	NN	_	_	_	_	_
20	(	_	_	-LRB-	_	_	_	_	_
21	PR	_	_	NN	_	_	_	_	_
22	)	_	_	-RRB-	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	and	_	_	CC	_	_	_	_	_
25	HER2	_	_	NN	_	_	_	_	_
26	amplification	_	_	NN	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	It	_	_	PRP	_	_	_	_	_
2	affects	_	_	VBZ	_	_	_	_	_
3	primarily	_	_	RB	_	_	_	_	_
4	younger	_	_	JJR	_	_	_	_	_
5	premenopausal	_	_	JJ	_	_	_	_	_
6	women	_	_	NNS	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	tends	_	_	VBZ	_	_	_	_	_
9	to	_	_	TO	_	_	_	_	_
10	have	_	_	VB	_	_	_	_	_
11	higher	_	_	JJR	_	_	_	_	_
12	incidences	_	_	NNS	_	_	_	_	_
13	in	_	_	IN	_	_	_	_	_
14	African	_	_	JJ	_	_	_	_	_
15	American	_	_	JJ	_	_	_	_	_
16	women	_	_	NNS	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	although	_	_	IN	_	_	_	_	_
19	recent	_	_	JJ	_	_	_	_	_
20	studies	_	_	NNS	_	_	_	_	_
21	reported	_	_	VBD	_	_	_	_	_
22	no	_	_	DT	_	_	_	_	_
23	differences	_	_	NNS	_	_	_	_	_
24	in	_	_	IN	_	_	_	_	_
25	clinical	_	_	JJ	_	_	_	_	_
26	outcomes	_	_	NNS	_	_	_	_	_
27	between	_	_	IN	_	_	_	_	_
28	Caucasian	_	_	JJ	_	_	_	_	_
29	and	_	_	CC	_	_	_	_	_
30	African	_	_	JJ	_	_	_	_	_
31	American	_	_	JJ	_	_	_	_	_
32	women	_	_	NNS	_	_	_	_	_
33	after	_	_	IN	_	_	_	_	_
34	adjusting	_	_	VBG	_	_	_	_	_
35	for	_	_	IN	_	_	_	_	_
36	socioeconomic	_	_	JJ	_	_	_	_	_
37	factors	_	_	NNS	_	_	_	_	_
38	.	_	_	.	_	_	_	_	_


1	Currently	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	there	_	_	EX	_	_	_	_	_
4	are	_	_	VBP	_	_	_	_	_
5	no	_	_	DT	_	_	_	_	_
6	effective	_	_	JJ	_	_	_	_	_
7	targeted	_	_	VBN	_	_	_	_	_
8	therapies	_	_	NNS	_	_	_	_	_
9	.	_	_	.	_	_	_	_	_


1	Cytotoxic	_	_	JJ	_	_	_	_	_
2	chemotherapy	_	_	NN	_	_	_	_	_
3	remains	_	_	VBZ	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	only	_	_	RB	_	_	_	_	_
6	effective	_	_	JJ	_	_	_	_	_
7	therapeutic	_	_	JJ	_	_	_	_	_
8	modality	_	_	NN	_	_	_	_	_
9	for	_	_	IN	_	_	_	_	_
10	this	_	_	DT	_	_	_	_	_
11	aggressive	_	_	JJ	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	often	_	_	RB	_	_	_	_	_
14	lethal	_	_	JJ	_	_	_	_	_
15	type	_	_	NN	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	breast	_	_	NN	_	_	_	_	_
18	cancer	_	_	NN	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	Therefore	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	there	_	_	EX	_	_	_	_	_
4	is	_	_	VBZ	_	_	_	_	_
5	an	_	_	DT	_	_	_	_	_
6	urgent	_	_	JJ	_	_	_	_	_
7	need	_	_	NN	_	_	_	_	_
8	for	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	discovery	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	molecular	_	_	JJ	_	_	_	_	_
13	markers	_	_	NNS	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	targets	_	_	NNS	_	_	_	_	_
16	for	_	_	IN	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	development	_	_	NN	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	novel	_	_	JJ	_	_	_	_	_
21	targeted	_	_	VBN	_	_	_	_	_
22	therapeutics	_	_	NNS	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	Our	_	_	PRP$	_	_	_	_	_
2	understanding	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	molecular	_	_	JJ	_	_	_	_	_
6	basis	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	TNBC	_	_	NNP	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	development	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	effective	_	_	JJ	_	_	_	_	_
13	targeted	_	_	VBN	_	_	_	_	_
14	therapies	_	_	NNS	_	_	_	_	_
15	has	_	_	VBZ	_	_	_	_	_
16	been	_	_	VBN	_	_	_	_	_
17	hampered	_	_	VBN	_	_	_	_	_
18	by	_	_	IN	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	complexity	_	_	NN	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	multifactorial	_	_	JJ	_	_	_	_	_
23	etiology	_	_	NN	_	_	_	_	_
24	of	_	_	IN	_	_	_	_	_
25	the	_	_	DT	_	_	_	_	_
26	disease	_	_	NN	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	Genes	_	_	NNS	_	_	_	_	_
2	play	_	_	VBP	_	_	_	_	_
3	a	_	_	DT	_	_	_	_	_
4	major	_	_	JJ	_	_	_	_	_
5	role	_	_	NN	_	_	_	_	_
6	in	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	pathogenesis	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	TNBC	_	_	NNP	_	_	_	_	_
11	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	majority	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	TNBC	_	_	NNP	_	_	_	_	_
5	patients	_	_	NNS	_	_	_	_	_
6	carry	_	_	VBP	_	_	_	_	_
7	mutations	_	_	NNS	_	_	_	_	_
8	in	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	highly	_	_	RB	_	_	_	_	_
11	penetrant	_	_	JJ	_	_	_	_	_
12	cancer	_	_	NN	_	_	_	_	_
13	susceptibility	_	_	NN	_	_	_	_	_
14	genes	_	_	NNS	_	_	_	_	_
15	BRCA1	_	_	NNP	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	BRCA2	_	_	NNP	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	unselected	_	_	JJ	_	_	_	_	_
3	TNBC	_	_	NN	_	_	_	_	_
4	cases	_	_	NNS	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	prevalence	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	pathogenic	_	_	JJ	_	_	_	_	_
10	germline	_	_	NN	_	_	_	_	_
11	BRCA1	_	_	NN	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	BRCA2	_	_	NN	_	_	_	_	_
14	mutations	_	_	NNS	_	_	_	_	_
15	is	_	_	VBZ	_	_	_	_	_
16	approximately	_	_	RB	_	_	_	_	_
17	twice	_	_	RB	_	_	_	_	_
18	as	_	_	RB	_	_	_	_	_
19	high	_	_	JJ	_	_	_	_	_
20	as	_	_	IN	_	_	_	_	_
21	in	_	_	IN	_	_	_	_	_
22	breast	_	_	NN	_	_	_	_	_
23	cancer	_	_	NN	_	_	_	_	_
24	overall	_	_	JJ	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	Apart	_	_	RB	_	_	_	_	_
2	from	_	_	IN	_	_	_	_	_
3	BRCA1	_	_	NNP	_	_	_	_	_
4	and	_	_	CC	_	_	_	_	_
5	BRCA2	_	_	NNP	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	rarely	_	_	RB	_	_	_	_	_
9	mutated	_	_	VBN	_	_	_	_	_
10	breast	_	_	NN	_	_	_	_	_
11	cancer	_	_	NN	_	_	_	_	_
12	predisposition	_	_	NN	_	_	_	_	_
13	genes	_	_	NNS	_	_	_	_	_
14	PALB2	_	_	NNP	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	FANCM	_	_	NNP	_	_	_	_	_
17	have	_	_	VBP	_	_	_	_	_
18	been	_	_	VBN	_	_	_	_	_
19	associated	_	_	VBN	_	_	_	_	_
20	with	_	_	IN	_	_	_	_	_
21	TNBC	_	_	NNP	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	Multigene	_	_	JJ	_	_	_	_	_
2	panel	_	_	NN	_	_	_	_	_
3	testing	_	_	NN	_	_	_	_	_
4	has	_	_	VBZ	_	_	_	_	_
5	also	_	_	RB	_	_	_	_	_
6	identified	_	_	VBN	_	_	_	_	_
7	genes	_	_	NNS	_	_	_	_	_
8	with	_	_	IN	_	_	_	_	_
9	high	_	_	JJ	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	moderate	_	_	JJ	_	_	_	_	_
12	penetrance	_	_	NN	_	_	_	_	_
13	associated	_	_	VBN	_	_	_	_	_
14	with	_	_	IN	_	_	_	_	_
15	an	_	_	DT	_	_	_	_	_
16	increased	_	_	VBN	_	_	_	_	_
17	risk	_	_	NN	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	developing	_	_	VBG	_	_	_	_	_
20	TNBC	_	_	NNP	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	although	_	_	IN	_	_	_	_	_
4	genes	_	_	NNS	_	_	_	_	_
5	may	_	_	MD	_	_	_	_	_
6	play	_	_	VB	_	_	_	_	_
7	a	_	_	DT	_	_	_	_	_
8	strong	_	_	JJ	_	_	_	_	_
9	role	_	_	NN	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	molecular	_	_	JJ	_	_	_	_	_
12	epidemiology	_	_	NN	_	_	_	_	_
13	studies	_	_	NNS	_	_	_	_	_
14	suggest	_	_	VBP	_	_	_	_	_
15	that	_	_	IN	_	_	_	_	_
16	TNBC	_	_	NNP	_	_	_	_	_
17	risk	_	_	NN	_	_	_	_	_
18	is	_	_	VBZ	_	_	_	_	_
19	largely	_	_	RB	_	_	_	_	_
20	determined	_	_	VBN	_	_	_	_	_
21	by	_	_	IN	_	_	_	_	_
22	interactions	_	_	NNS	_	_	_	_	_
23	between	_	_	IN	_	_	_	_	_
24	genes	_	_	NNS	_	_	_	_	_
25	and	_	_	CC	_	_	_	_	_
26	environment	_	_	NN	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	Increased	_	_	VBN	_	_	_	_	_
2	attention	_	_	NN	_	_	_	_	_
3	has	_	_	VBZ	_	_	_	_	_
4	focused	_	_	VBN	_	_	_	_	_
5	on	_	_	IN	_	_	_	_	_
6	epigenetic	_	_	JJ	_	_	_	_	_
7	variation	_	_	NN	_	_	_	_	_
8	such	_	_	JJ	_	_	_	_	_
9	as	_	_	IN	_	_	_	_	_
10	DNA	_	_	NN	_	_	_	_	_
11	methylation	_	_	NN	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	TNBC	_	_	NNP	_	_	_	_	_
14	because	_	_	IN	_	_	_	_	_
15	enduring	_	_	VBG	_	_	_	_	_
16	epigenetic	_	_	JJ	_	_	_	_	_
17	landmarks	_	_	NNS	_	_	_	_	_
18	define	_	_	VBP	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	tumor	_	_	NN	_	_	_	_	_
21	microenvironment	_	_	NN	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	Moreover	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	because	_	_	IN	_	_	_	_	_
4	DNA	_	_	NN	_	_	_	_	_
5	methylation	_	_	NN	_	_	_	_	_
6	regulates	_	_	VBZ	_	_	_	_	_
7	gene	_	_	NN	_	_	_	_	_
8	expression	_	_	NN	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	aberrant	_	_	JJ	_	_	_	_	_
11	methylated	_	_	JJ	_	_	_	_	_
12	genes	_	_	NNS	_	_	_	_	_
13	could	_	_	MD	_	_	_	_	_
14	serve	_	_	VB	_	_	_	_	_
15	as	_	_	IN	_	_	_	_	_
16	complementary	_	_	JJ	_	_	_	_	_
17	diagnostic	_	_	JJ	_	_	_	_	_
18	tools	_	_	NNS	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	prognostic	_	_	JJ	_	_	_	_	_
21	markers	_	_	NNS	_	_	_	_	_
22	and	_	_	CC	_	_	_	_	_
23	predictors	_	_	NNS	_	_	_	_	_
24	of	_	_	IN	_	_	_	_	_
25	response	_	_	NN	_	_	_	_	_
26	to	_	_	TO	_	_	_	_	_
27	treatment	_	_	NN	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_


1	Thus	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	a	_	_	DT	_	_	_	_	_
4	critical	_	_	JJ	_	_	_	_	_
5	knowledge	_	_	NN	_	_	_	_	_
6	gap	_	_	NN	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	and	_	_	CC	_	_	_	_	_
9	an	_	_	DT	_	_	_	_	_
10	unmet	_	_	JJ	_	_	_	_	_
11	medical	_	_	JJ	_	_	_	_	_
12	need	_	_	NN	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	is	_	_	VBZ	_	_	_	_	_
15	understanding	_	_	VBG	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	interplay	_	_	NN	_	_	_	_	_
18	between	_	_	IN	_	_	_	_	_
19	genetic	_	_	JJ	_	_	_	_	_
20	(	_	_	-LRB-	_	_	_	_	_
21	both	_	_	CC	_	_	_	_	_
22	germline	_	_	JJ	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	somatic	_	_	JJ	_	_	_	_	_
25	)	_	_	-RRB-	_	_	_	_	_
26	variation	_	_	NN	_	_	_	_	_
27	and	_	_	CC	_	_	_	_	_
28	epigenomic	_	_	JJ	_	_	_	_	_
29	variation	_	_	NN	_	_	_	_	_
30	in	_	_	IN	_	_	_	_	_
31	TNBC	_	_	NNP	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_


1	Advances	_	_	NNS	_	_	_	_	_
2	in	_	_	IN	_	_	_	_	_
3	microarray	_	_	NN	_	_	_	_	_
4	technology	_	_	NN	_	_	_	_	_
5	have	_	_	VBP	_	_	_	_	_
6	enabled	_	_	VBN	_	_	_	_	_
7	molecular	_	_	JJ	_	_	_	_	_
8	classification	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	subtypes	_	_	NNS	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	TNBC	_	_	NNP	_	_	_	_	_
13	.	_	_	.	_	_	_	_	_


1	At	_	_	IN	_	_	_	_	_
2	least	_	_	JJS	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	several	_	_	JJ	_	_	_	_	_
5	clinically	_	_	RB	_	_	_	_	_
6	validated	_	_	VBN	_	_	_	_	_
7	prognostic	_	_	JJ	_	_	_	_	_
8	assays	_	_	NNS	_	_	_	_	_
9	including	_	_	VBG	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	Prosigna	_	_	NNP	_	_	_	_	_
12	PAM50	_	_	NNP	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	MammaPrint	_	_	NNP	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	Oncotype	_	_	NNP	_	_	_	_	_
17	DX	_	_	NNP	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	have	_	_	VBP	_	_	_	_	_
20	been	_	_	VBN	_	_	_	_	_
21	developed	_	_	VBN	_	_	_	_	_
22	using	_	_	VBG	_	_	_	_	_
23	transcription	_	_	NN	_	_	_	_	_
24	profiling	_	_	NN	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	although	_	_	IN	_	_	_	_	_
4	these	_	_	DT	_	_	_	_	_
5	primary	_	_	JJ	_	_	_	_	_
6	analyses	_	_	NNS	_	_	_	_	_
7	have	_	_	VBP	_	_	_	_	_
8	been	_	_	VBN	_	_	_	_	_
9	successful	_	_	JJ	_	_	_	_	_
10	in	_	_	IN	_	_	_	_	_
11	identifying	_	_	VBG	_	_	_	_	_
12	prognostic	_	_	JJ	_	_	_	_	_
13	markers	_	_	NNS	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	they	_	_	PRP	_	_	_	_	_
16	have	_	_	VBP	_	_	_	_	_
17	been	_	_	VBN	_	_	_	_	_
18	unsuccessful	_	_	JJ	_	_	_	_	_
19	in	_	_	IN	_	_	_	_	_
20	establishing	_	_	VBG	_	_	_	_	_
21	the	_	_	DT	_	_	_	_	_
22	causal	_	_	JJ	_	_	_	_	_
23	association	_	_	NN	_	_	_	_	_
24	between	_	_	IN	_	_	_	_	_
25	gene	_	_	NN	_	_	_	_	_
26	expression	_	_	NN	_	_	_	_	_
27	and	_	_	CC	_	_	_	_	_
28	the	_	_	DT	_	_	_	_	_
29	disease	_	_	NN	_	_	_	_	_
30	.	_	_	.	_	_	_	_	_


1	High-throughput	_	_	JJ	_	_	_	_	_
2	genotyping	_	_	NN	_	_	_	_	_
3	using	_	_	VBG	_	_	_	_	_
4	genome-wide	_	_	JJ	_	_	_	_	_
5	association	_	_	NN	_	_	_	_	_
6	studies	_	_	NNS	_	_	_	_	_
7	(	_	_	-LRB-	_	_	_	_	_
8	GWAS	_	_	NNP	_	_	_	_	_
9	)	_	_	-RRB-	_	_	_	_	_
10	has	_	_	VBZ	_	_	_	_	_
11	enabled	_	_	VBN	_	_	_	_	_
12	discovery	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	genetic	_	_	JJ	_	_	_	_	_
15	variants	_	_	NNS	_	_	_	_	_
16	associated	_	_	VBN	_	_	_	_	_
17	with	_	_	IN	_	_	_	_	_
18	an	_	_	DT	_	_	_	_	_
19	increased	_	_	VBN	_	_	_	_	_
20	risk	_	_	NN	_	_	_	_	_
21	of	_	_	IN	_	_	_	_	_
22	developing	_	_	VBG	_	_	_	_	_
23	TNBC	_	_	NNP	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	recent	_	_	JJ	_	_	_	_	_
3	surge	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	next	_	_	JJ	_	_	_	_	_
6	generation	_	_	NN	_	_	_	_	_
7	sequencing	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	tumor	_	_	NN	_	_	_	_	_
10	genomes	_	_	NNS	_	_	_	_	_
11	by	_	_	IN	_	_	_	_	_
12	large	_	_	JJ	_	_	_	_	_
13	multicenter	_	_	NN	_	_	_	_	_
14	projects	_	_	NNS	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	such	_	_	JJ	_	_	_	_	_
17	as	_	_	IN	_	_	_	_	_
18	The	_	_	DT	_	_	_	_	_
19	Cancer	_	_	NNP	_	_	_	_	_
20	Genome	_	_	NNP	_	_	_	_	_
21	Atlas	_	_	NNP	_	_	_	_	_
22	(	_	_	-LRB-	_	_	_	_	_
23	TCGA	_	_	NNP	_	_	_	_	_
24	)	_	_	-RRB-	_	_	_	_	_
25	and	_	_	CC	_	_	_	_	_
26	the	_	_	DT	_	_	_	_	_
27	International	_	_	NNP	_	_	_	_	_
28	Cancer	_	_	NNP	_	_	_	_	_
29	Genome	_	_	NNP	_	_	_	_	_
30	Consortium	_	_	NNP	_	_	_	_	_
31	(	_	_	-LRB-	_	_	_	_	_
32	ICGC	_	_	NNP	_	_	_	_	_
33	)	_	_	-RRB-	_	_	_	_	_
34	,	_	_	,	_	_	_	_	_
35	have	_	_	VBP	_	_	_	_	_
36	generated	_	_	VBN	_	_	_	_	_
37	comprehensive	_	_	JJ	_	_	_	_	_
38	catalogues	_	_	NNS	_	_	_	_	_
39	of	_	_	IN	_	_	_	_	_
40	somatic	_	_	JJ	_	_	_	_	_
41	mutations	_	_	NNS	_	_	_	_	_
42	associated	_	_	VBN	_	_	_	_	_
43	with	_	_	IN	_	_	_	_	_
44	TNBC	_	_	NNP	_	_	_	_	_
45	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	clonal	_	_	JJ	_	_	_	_	_
3	and	_	_	CC	_	_	_	_	_
4	mutational	_	_	JJ	_	_	_	_	_
5	spectrum	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	primary	_	_	JJ	_	_	_	_	_
8	TNBCs	_	_	NNPS	_	_	_	_	_
9	have	_	_	VBP	_	_	_	_	_
10	also	_	_	RB	_	_	_	_	_
11	been	_	_	VBN	_	_	_	_	_
12	characterized	_	_	VBN	_	_	_	_	_
13	.	_	_	.	_	_	_	_	_


1	We	_	_	PRP	_	_	_	_	_
2	recently	_	_	RB	_	_	_	_	_
3	reported	_	_	VBD	_	_	_	_	_
4	oncogenic	_	_	JJ	_	_	_	_	_
5	interactions	_	_	NNS	_	_	_	_	_
6	between	_	_	IN	_	_	_	_	_
7	genes	_	_	NNS	_	_	_	_	_
8	containing	_	_	VBG	_	_	_	_	_
9	germline	_	_	NN	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	somatic	_	_	JJ	_	_	_	_	_
12	mutations	_	_	NNS	_	_	_	_	_
13	in	_	_	IN	_	_	_	_	_
14	TNBC	_	_	NNP	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	to	_	_	TO	_	_	_	_	_
4	date	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	information	_	_	NN	_	_	_	_	_
7	on	_	_	IN	_	_	_	_	_
8	germline	_	_	NN	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	somatic	_	_	JJ	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	gene	_	_	NN	_	_	_	_	_
13	expression	_	_	NN	_	_	_	_	_
14	variation	_	_	NN	_	_	_	_	_
15	has	_	_	VBZ	_	_	_	_	_
16	not	_	_	RB	_	_	_	_	_
17	been	_	_	VBN	_	_	_	_	_
18	leveraged	_	_	VBN	_	_	_	_	_
19	and	_	_	CC	_	_	_	_	_
20	integrated	_	_	VBN	_	_	_	_	_
21	with	_	_	IN	_	_	_	_	_
22	DNA	_	_	NN	_	_	_	_	_
23	methylation	_	_	NN	_	_	_	_	_
24	data	_	_	NNS	_	_	_	_	_
25	to	_	_	TO	_	_	_	_	_
26	map	_	_	VB	_	_	_	_	_
27	the	_	_	DT	_	_	_	_	_
28	interplay	_	_	NN	_	_	_	_	_
29	between	_	_	IN	_	_	_	_	_
30	genetic	_	_	JJ	_	_	_	_	_
31	and	_	_	CC	_	_	_	_	_
32	epigenetic	_	_	JJ	_	_	_	_	_
33	variation	_	_	NN	_	_	_	_	_
34	in	_	_	IN	_	_	_	_	_
35	TNBC	_	_	NNP	_	_	_	_	_
36	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	limited	_	_	JJ	_	_	_	_	_
3	progress	_	_	NN	_	_	_	_	_
4	must	_	_	MD	_	_	_	_	_
5	be	_	_	VB	_	_	_	_	_
6	balanced	_	_	VBN	_	_	_	_	_
7	against	_	_	IN	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	recognition	_	_	NN	_	_	_	_	_
10	that	_	_	IN	_	_	_	_	_
11	genomic	_	_	JJ	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	epigenomic	_	_	JJ	_	_	_	_	_
14	alterations	_	_	NNS	_	_	_	_	_
15	have	_	_	VBP	_	_	_	_	_
16	long	_	_	RB	_	_	_	_	_
17	been	_	_	VBN	_	_	_	_	_
18	considered	_	_	VBN	_	_	_	_	_
19	as	_	_	IN	_	_	_	_	_
20	two	_	_	CD	_	_	_	_	_
21	separate	_	_	JJ	_	_	_	_	_
22	molecular	_	_	JJ	_	_	_	_	_
23	mechanisms	_	_	NNS	_	_	_	_	_
24	participating	_	_	VBG	_	_	_	_	_
25	in	_	_	IN	_	_	_	_	_
26	TNBC	_	_	NNP	_	_	_	_	_
27	pathogenesis	_	_	NN	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	objective	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	this	_	_	DT	_	_	_	_	_
5	investigation	_	_	NN	_	_	_	_	_
6	is	_	_	VBZ	_	_	_	_	_
7	to	_	_	TO	_	_	_	_	_
8	deconvolute	_	_	VB	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	genomic	_	_	JJ	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	epigenomic	_	_	JJ	_	_	_	_	_
13	interaction	_	_	NN	_	_	_	_	_
14	landscape	_	_	NN	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	to	_	_	TO	_	_	_	_	_
18	discover	_	_	VB	_	_	_	_	_
19	and	_	_	CC	_	_	_	_	_
20	characterize	_	_	VB	_	_	_	_	_
21	the	_	_	DT	_	_	_	_	_
22	molecular	_	_	JJ	_	_	_	_	_
23	networks	_	_	NNS	_	_	_	_	_
24	and	_	_	CC	_	_	_	_	_
25	signaling	_	_	VBG	_	_	_	_	_
26	pathways	_	_	NNS	_	_	_	_	_
27	perturbed	_	_	VBN	_	_	_	_	_
28	by	_	_	IN	_	_	_	_	_
29	these	_	_	DT	_	_	_	_	_
30	interactions	_	_	NNS	_	_	_	_	_
31	in	_	_	IN	_	_	_	_	_
32	TNBC	_	_	NNP	_	_	_	_	_
33	.	_	_	.	_	_	_	_	_


1	Our	_	_	PRP$	_	_	_	_	_
2	working	_	_	VBG	_	_	_	_	_
3	hypothesis	_	_	NN	_	_	_	_	_
4	was	_	_	VBD	_	_	_	_	_
5	that	_	_	IN	_	_	_	_	_
6	TNBC	_	_	NNP	_	_	_	_	_
7	originates	_	_	VBZ	_	_	_	_	_
8	from	_	_	IN	_	_	_	_	_
9	a	_	_	DT	_	_	_	_	_
10	complex	_	_	JJ	_	_	_	_	_
11	interplay	_	_	NN	_	_	_	_	_
12	between	_	_	IN	_	_	_	_	_
13	genomic	_	_	JJ	_	_	_	_	_
14	(	_	_	-LRB-	_	_	_	_	_
15	both	_	_	CC	_	_	_	_	_
16	germline	_	_	JJ	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	somatic	_	_	JJ	_	_	_	_	_
19	)	_	_	-RRB-	_	_	_	_	_
20	variation	_	_	NN	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	epigenomic	_	_	JJ	_	_	_	_	_
23	variations	_	_	NNS	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	We	_	_	PRP	_	_	_	_	_
2	further	_	_	RB	_	_	_	_	_
3	hypothesized	_	_	VBD	_	_	_	_	_
4	that	_	_	IN	_	_	_	_	_
5	these	_	_	DT	_	_	_	_	_
6	complex	_	_	JJ	_	_	_	_	_
7	arrays	_	_	NNS	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	interacting	_	_	VBG	_	_	_	_	_
10	genomic	_	_	JJ	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	epigenomic	_	_	JJ	_	_	_	_	_
13	factors	_	_	NNS	_	_	_	_	_
14	affect	_	_	VBP	_	_	_	_	_
15	entire	_	_	JJ	_	_	_	_	_
16	molecular	_	_	JJ	_	_	_	_	_
17	networks	_	_	NNS	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	signaling	_	_	VBG	_	_	_	_	_
20	pathways	_	_	NNS	_	_	_	_	_
21	which	_	_	WDT	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	in	_	_	IN	_	_	_	_	_
24	turn	_	_	NN	_	_	_	_	_
25	,	_	_	,	_	_	_	_	_
26	drive	_	_	VBP	_	_	_	_	_
27	TNBC	_	_	NNP	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_


1	We	_	_	PRP	_	_	_	_	_
2	addressed	_	_	VBD	_	_	_	_	_
3	these	_	_	DT	_	_	_	_	_
4	hypotheses	_	_	NNS	_	_	_	_	_
5	by	_	_	IN	_	_	_	_	_
6	integrating	_	_	VBG	_	_	_	_	_
7	information	_	_	NN	_	_	_	_	_
8	on	_	_	IN	_	_	_	_	_
9	germline	_	_	NN	_	_	_	_	_
10	variation	_	_	NN	_	_	_	_	_
11	from	_	_	IN	_	_	_	_	_
12	GWAS	_	_	NN	_	_	_	_	_
13	with	_	_	IN	_	_	_	_	_
14	information	_	_	NN	_	_	_	_	_
15	on	_	_	IN	_	_	_	_	_
16	somatic	_	_	JJ	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	epigenomic	_	_	JJ	_	_	_	_	_
19	variation	_	_	NN	_	_	_	_	_
20	from	_	_	IN	_	_	_	_	_
21	TCGA	_	_	NNP	_	_	_	_	_
22	using	_	_	VBG	_	_	_	_	_
23	gene	_	_	NN	_	_	_	_	_
24	expression	_	_	NN	_	_	_	_	_
25	as	_	_	IN	_	_	_	_	_
26	the	_	_	DT	_	_	_	_	_
27	intermediated	_	_	JJ	_	_	_	_	_
28	phenotype	_	_	NN	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_

